13D Filing: Redmile Group and Alder Biopharmaceuticals Inc (ALDR)
...... (read more)
The San Francisco-based Redmile Group is managed by Jeremy Green, and has an equity portfolio that focuses almost exclusively on the healthcare sector.
Hedge Fund - Redmile Group
Get Email AlertsJeremy Green Bio, Returns, AUM, Net Worth
Fund Profile
Filing Period:
| Fund Name: | Redmile Group |
| Manager | Jeremy Green |
| Portfolio Value | $4,180,807,000 |
| Change This QTR | +1.40% |
Top 13F Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Security | Ticker | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|---|
| 1. | DCPH | 4,709,498 | $293,119 | -2% | 7.01% | |
| 2. | ALLK | 3,033,526 | $289,277 | -2% | 6.91% | |
| 3. | FOLD | 25,209,964 | $245,545 | +11% | 5.87% | |
| 4. | FATE | 11,216,809 | $219,513 | 5.25% | ||
| 5. | EPZM | 8,746,033 | $215,152 | +2% | 5.14% |
Latest 13D & 13G Filings
| Company | Symbol | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2019-10-24 | ||||
| 2019-10-09 | ||||
| 2019-09-24 | ||||
| 2019-09-17 |
News, Interviews and Investor Letters
13G Filing: Redmile Group and Fate Therapeutics Inc (FATE)
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject...... (read more)
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management and investment banking...... (read more)
Redmile Group’s Top Q4 Moves as Its Long Positions Show Gains of 20% in 2015
Redmile Group is a San Francisco-based investment firm managed by Jeremy Green, which primarily focuses on the healthcare sector. Redmile has an equity portfolio worth nearly $1.34 billion as of the end...... (read more)
Billionaires James Flynn, David Abrams, Among the Elite Investors Buying These 4 Stocks Last Week
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ. However, mimicking what successful hedge fund managers do comes at...... (read more)
Buffett, Starboard Among the Elite Investors to Disclose New Moves
The deadline for the current round of 13F filings, for the quarterly period that ended December 31, is February 15. Most market participants find these quarterly filings informative, as they reveal the...... (read more)
Redmile Group Continues To Agressively Buy Shares Of This Biotech
In a recent filing with the SEC, Jeremy Green's Redmile Group, which has been consistently accumulating shares of Array Biopharma Inc (NASDAQ:ARRY) for the past seven quarters, revealed that it has yet...... (read more)
Redmile Group Fortifies Position In Array Biopharma Inc (ARRY); Broadwood Capital Boosts Stake In STAAR Surgical Company (STAA)
Jeremy Green, the manager of Redmile Group, is still bullish on Array Biopharma Inc (NASDAQ:ARRY) having further increased his holding of the stock. As reported in a recent Form 4 filing with the Securities...... (read more)
Redmile Group Is Putting More Money Into Array BioPharma Inc. (ARRY)
Jeremy Green’s Redmile Group has just acquired more shares of Array BioPharma Inc. (NASDAQ:ARRY). In a Form 4 filed with the U.S. Securities and Exchange Commission, Redmile Group disclosed purchases...... (read more)
Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Group’s Top New Picks
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February. The hedge fund is particularly...... (read more)
Amicus Therapeutics, Inc. (FOLD): Redmile Group Trims Position and Books Some Profits from Long-Term Investment
Jeremy Green's Redmile Group has also reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD), after yesterday, William Leland Edwards’ Palo Alto Investors reported the sale of nearly a half...... (read more)
